Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Teva
Chubb
AstraZeneca
Harvard Business School
Colorcon
Daiichi Sankyo
Chinese Patent Office

Generated: May 22, 2018

DrugPatentWatch Database Preview

TAVIST-1 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Tavist-1 patents expire, and when can generic versions of Tavist-1 launch?

Tavist-1 is a drug marketed by Glaxosmithkline Cons and Novartis and is included in two NDAs.

The generic ingredient in TAVIST-1 is clemastine fumarate. There are two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the clemastine fumarate profile page.
Summary for TAVIST-1
Drug patent expirations by year for TAVIST-1
Medical Subject Heading (MeSH) Categories for TAVIST-1
Synonyms for TAVIST-1
(+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine fumarate (1:1)
(+)-2-(2-((p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl pyrrolidine fumarate
(2R)-2-[2-[(1R)-1-(4-Chlorophenylethoxy]ethyl]-1-methyl-2-pyrrolidine fumarate
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine (2E)-but-2-enedioate
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidinium (2E)-3-carboxyprop-2-enoate
(E)-but-2-enedioic acid; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
(E)-but-2-enedioic acid;(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
(R-(R*,R*))-2-(2-(1-(p-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidinium hydrogen fumarate
(R)-2-(2-((R)-1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine fumarate
(R)-2-[2-[(R)-1-(4-Chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine fumarate
14976-57-9
19259EGQ3D
976C579
AB2000329
AC-1338
AC1NQXZB
Agasten
AK163209
AKOS015896237
Aloginan
Alphamin
Anhistan
AS-12093
BC206422
C21H26ClNO.C4H4O4
CAS-14976-57-9
CCG-40028
CHEBI:3739
CHEMBL1200795
Clemanil
Clemastine (fumarate)
Clemastine for system suitability, European Pharmacopoeia (EP) Reference Standard
CLEMASTINE FUMARATE
Clemastine fumarate [USAN:BAN:JAN]
Clemastine fumarate [USAN:USP:BAN:JAN]
Clemastine fumarate salt, >=98% (HPLC)
Clemastine fumarate, European Pharmacopoeia (EP) Reference Standard
Clemastine fumarate, United States Pharmacopeia (USP) Reference Standard
Clemastine hydrogen fumarate
clemastine; fumaric acid
Contac 12 Hour Allergy
CS-2331
DSSTox_CID_27765
DSSTox_GSID_47785
DSSTox_RID_82542
DTXSID6047785
EINECS 239-055-2
Fuluminol
HE069307
HMS1568N14
HMS1920O13
HMS2091E20
HMS2095N14
HMS3267L12
HMS500O07
HSDB 6507
HY-B0298A
I06-2109
Inbestan
K-4763
Kinotomin
Lacretin
Lecasol
LS-137507
Maikohis
Mallermin-F
Marsthine
Masletine
Meclastine hydrogen fumarate
Mecloprodine
MFCD00137486
MolPort-003-666-146
NCGC00016710-01
NCGC00016710-05
NCGC00180903-01
NCGC00180903-02
NSC-756685
NSC756685
Pharmakon1600-01500191
Piloral
PMGQWSIVQFOFOQ-YKVZVUFRSA-N
Prestwick_680
Pyrrolidine, 2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl-, (+)-, fumarate (1:1)
Pyrrolidine, 2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl-, (+)-,fumarate (1:1)
Pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (R-(R*,R*))-, (E)-2-butenedioate (1:1)
Reconin
s1847
SCHEMBL33403
SCHEMBL41468
SPECTRUM1500191
ST24046356
ST51053374
Tavegil
Tavegyl
Tavist
Tavist;Xolamin;Agasten;Aloginan
Telgin-G
Topcare dayhist allergy
Tox21_110574
Tox21_110574_1
Trabest
UNII-19259EGQ3D
Xolamin

US Patents and Regulatory Information for TAVIST-1

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons TAVIST-1 clemastine fumarate TABLET;ORAL 020925-001 Aug 21, 1992 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis TAVIST-1 clemastine fumarate TABLET;ORAL 017661-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis TAVIST-1 clemastine fumarate TABLET;ORAL 017661-003 Aug 21, 1992 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Dow
QuintilesIMS
Harvard Business School
Cipla
Moodys
Queensland Health
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.